On July 17, 2026, Australian pharma company LTR Pharma announced it had executed a definitive US telehealth distribution agreement with Shed Holdings LLC, converting a previously announced binding term sheet into a full commercial contract to sell ROXUS — its fast-acting intranasal erectile-dysfunction spray — to American consumers. The deal establishes the commercial framework for LTR's planned US market entry and, according to reporting on the announcement, covers an initial supply commitment in the range of 150,000 units. Shed, a direct-to-consumer telehealth platform, will handle marketing and patient acquisition, while a separately announced pharmacy partner, Strive Specialties (a US 503A compounding pharmacy signed in June 2026), provides the fulfillment infrastructure.

Why It Matters

Erectile dysfunction is the anchor category of the entire men's-health telehealth boom, and format innovation — not molecule innovation — is increasingly where new entrants compete. This week's news slots neatly alongside a wave of delivery-format plays Afterglow has tracked: VYBRIQUE's dissolvable sildenafil oral film, Aspargo's liquid sildenafil spray seeking UK OTC status, and Vigo MD's daily ED gum. A nasal spray promising a 10-minute onset is the most aggressive speed claim in that pack, and if the efficacy and safety data hold up through a US NDA, it could pressure incumbents who currently differentiate on convenience and discretion rather than raw pharmacokinetics. For investors, the deal is a reminder that ASX-listed and other non-US sextech and men's-health companies increasingly view the US DTC telehealth channel as the fastest path to revenue — and that compounding pharmacies remain the industry's regulatory gray zone, the same channel that has drawn FDA scrutiny in the GLP-1 and testosterone fights. Execution risk is real: an initial supply commitment is not the same as sell-through, and the company's own language stresses that US commercialisation remains "planned." But the signing converts intent into contract, and it puts another differentiated ED format on a collision course with the Hims-and-Ro duopoly.

ROXUS is the US commercial name for LTR's SPONTAN platform (drug code SDS-089), a nasal PDE5-inhibitor delivery system the company markets as producing an erection in roughly 10 minutes or less — versus the 30-to-60-minute onset of oral sildenafil and tadalafil tablets. By delivering the active drug intranasally rather than through the gut, LTR argues it can sidestep first-pass metabolism and deliver faster, more predictable results, the pitch being a "first-in-class" rapid treatment aimed squarely at the established oral-PDE5 market.

The Shed agreement matters because distribution — not chemistry — is the usual choke point for a foreign ED entrant trying to crack the United States. The US ED market is dominated by well-capitalized telehealth players (Hims & Hers, Ro, BlueChew, LifeMD) that own the customer-acquisition funnel. By plugging into an existing DTC telehealth platform for prescribing and a 503A pharmacy for compounding and shipping, LTR gets a turnkey route to patients without building its own clinical or logistics stack. LTR has said it is pursuing a fast-track US NDA filing within roughly two years; in the interim, the compounding-pharmacy channel is a common (if regulatorily sensitive) on-ramp used across the men's-health telehealth space.

Sources

Update — 2026-07-17

Initial entry — story first created.

Update — 2026-07-20

LTR Pharma firmed up the fulfillment side of its US push. Over the July 19–20, 2026 weekend, the ASX-listed company announced it had executed a definitive agreement with Strive Pharmacy to establish U.S. manufacturing and national distribution for ROXUS — converting the earlier compounding-pharmacy arrangement into a formal manufacturing-and-distribution partnership. Paired with the Shed telehealth distribution deal signed days earlier, LTR now has both the patient-acquisition channel (Shed) and the domestic make-and-ship infrastructure (Strive) in place for its intranasal ED spray, with shares in focus on the ASX following the announcement.

The two deals together complete the turnkey US go-to-market stack Afterglow flagged in the original entry: prescribe via DTC telehealth, compound and ship via a domestic 503A pharmacy. The reliance on the compounding channel remains the strategy's regulatory soft spot — the same gray zone drawing FDA scrutiny across the GLP-1 and testosterone telehealth fights — but LTR has now locked in the operational pieces to begin US commercialisation ahead of a planned NDA filing.

New Sources